A prostatic agent refers to any drugs or substances which target the prostatic cells.
Pertaining to the prostate is prostatic, as in prostatic carcinoma.
The ejaculatory duct opens into the prostatic part of the urethra, specifically where the prostatic urethra meets with the membranous urethra. This junction is located within the prostate gland.
The abbreviation 'BPH' can mean benign prostatic hypertrophy or hyperplasia. They are coded differently. 600.00 benign prostatic hypertrophy without obstruction 600.01 benign prostatic hypertrophy with obstruction 600.90 benign prostatic hyperplasia without obstruction 600.91 benign prostatic hyperplasia with obstruction
J. E. Castro has written: 'The treatment of prostatic hypertrophy and neoplasia' -- subject(s): Cancer, Hypertrophy, Prostate, Prostatic Hypertrophy, Prostatic Neoplasms, Therapy
BPH is the medical abbreviation meaning benign prostatic hypertrophy.
Prostatorrhea is the abnormal flow of prostatic fluid.
Urethra has three regions in males, the prostatic urethra, membranous urethra, and the spongy urethra.
No, a benign prostatic hyperplasia (BPH) does not cause a cancerous enlargement of the prostate. A BPH is not cancerous. It is defined as a noncancerous enlargement of the prostate gland.
If the prostatic urethra gets clogged, a striction occurs. Treatment for this condition includes urethrotomy, antibiotics, surgery and stenting.
Alexander Randall has written: 'Surgical pathology of prostatic obstructions' -- subject(s): Prostatic Diseases, Pathology, Surgery
Prostatic fluid
If the prostate enlarges and compresses the urethra, it is called benign prostatic hyperplasia (BPH). This condition can lead to lower urinary tract symptoms such as increased frequency and urgency of urination.